{"id":474043,"date":"2020-03-16T10:38:01","date_gmt":"2020-03-16T10:38:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=474043"},"modified":"2020-03-16T10:38:01","modified_gmt":"2020-03-16T10:38:01","slug":"hepatocellular-carcinoma-market-insights-epidemiology-and-market-forecast-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/hepatocellular-carcinoma-market-insights-epidemiology-and-market-forecast-2030_474043.html","title":{"rendered":"Hepatocellular Carcinoma Market Insights, Epidemiology, and Market Forecast 2030"},"content":{"rendered":"
\"Hepatocellular<\/a><\/div>\n

Albany, US –<\/strong> DelveInsight launched its new report on Hepatocellular Carcinoma – Market Insights, Epidemiology, and Market Forecast 2030<\/a><\/p>\n

DelveInsight’s “Hepatocellular Carcinoma – Market Insights, Epidemiology, and Market Forecast-2030<\/strong>” report delivers an in-depth understanding of the Hepatocellular Carcinoma, historical and forecasted epidemiology as well as the Hepatocellular Carcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

Some of the key facts of the report:<\/strong>
1. Hepatocellular Carcinoma in G8 countries were 4, 60,992 in 2017.
2. The total Diagnosed Advanced HCC cases in G8 countries were 1, 61,790 cases in 2017.
3. The total patients in G8 countries on first and second-line therapies were 41,036 and 14,866 respectively, and the treatment available patient pool on these therapies is expected to rise owing to the increase in the disease burden during the forecast period (2019-2028).<\/p>\n

Key benefits of the report:<\/strong>
1. Hepatocellular Carcinoma market report covers a descriptive overview and comprehensive insight of the Hepatocellular Carcinoma Epidemiology and Hepatocellular Carcinoma market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Hepatocellular Carcinoma market report provides insights on the current and emerging therapies.
3. Hepatocellular Carcinoma market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Hepatocellular Carcinoma market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Hepatocellular Carcinoma market.<\/p>\n

Request for sample pages<\/strong>: https:\/\/www.delveinsight.com\/sample-request\/hepatocellular-carcinoma-market<\/p>\n

\"\"<\/p>\n

Hepatocellular Carcinoma (HCC) is the most common type of primary liver cancer. It is a malignant tumor of hepatocytes, may exhibit any or all of the cytologic and\/or architectural characteristics of hepatocellular differentiation, along with features of malignancy. Hepatocellular Carcinoma (HCC) is the fifth most common cause of cancer, and its incidence is increasing worldwide because of the dissemination of Hepatitis B and C virus infection.<\/p>\n

Key pharma players involved in Hepatocellular carcinoma market:<\/strong>
1. Jiangsu HengRui Medicine
2. AstraZeneca
And many others<\/p>\n

Hepatocellular Carcinoma Drugs Market:<\/strong>
Drugs covered
1. SHR-1210
2. Durvalumab plus Tremelimumab
And many others<\/p>\n

Download a free sample report<\/strong>: https:\/\/www.delveinsight.com\/sample-request\/hepatocellular-carcinoma-market<\/p>\n

Table of contents<\/strong>
1. Key Insights
2. Hepatocellular Carcinoma Market Overview at a Glance
3. Hepatocellular Carcinoma Disease Background and Overview
4. Hepatocellular Carcinoma Epidemiology and Patient Population
5. Key Findings
6. Population and Forecast Parameters
7. Country Wise Hepatocellular Carcinoma Epidemiology
7.1. United States
7.2. EU5 Countries
7.3. Germany
7.4. France
7.5. Italy
7.6. Spain
7.7. United Kingdom
7.8. Japan
7.9. China
8. Hepatocellular Carcinoma Treatment Practices
9. Unmet Needs
10. Hepatocellular Carcinoma Marketed Drug Analysis
10.1.Nexavar: Bayer HealthCare
10.2.Miripla: Sumitomo Dainippon Pharma
10.3.Opdivo: Bristol-Myers Squibb
11. Hepatocellular Carcinoma Emerging Therapies
12. Hepatocellular Carcinoma Emerging Drugs Analysis
12.1.Durvalumab plus Tremelimumab: AstraZeneca
12.2. SHR-1210: Jiangsu HengRui Medicine
13. Failure in Phase III Clinical trials for Hepatocellular Carcinoma
14. Hepatocellular Carcinoma G8 Countries Market Analysis
15. Key Findings
16. Market Outlook by Country
16.1.The United States: Market Outlook
16.2.EU-5 Countries: Market Outlook
16.3.Germany
16.4.France
16.5.Italy
16.6.Spain
16.7.United Kingdom
16.8.Japan: Market Outlook
16.9.China: Market Outlook
17. Market Drivers
18. Market Barriers
19. Appendix
20. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight<\/p>\n

Related Reports:<\/strong><\/p>\n

Hepatocellular Carcinoma – Epidemiology Forecast to 2030<\/a><\/p>\n

Hepatocellular Carcinoma Pipeline Insight, 2020<\/a><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Yash Bhardwaj
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 9193216187
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Las Vegas
State:<\/strong> NEVADA 89107
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Albany, US – DelveInsight launched its new report on Hepatocellular Carcinoma – Market Insights, Epidemiology, and Market Forecast 2030 DelveInsight’s “Hepatocellular Carcinoma – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Hepatocellular Carcinoma, historical and forecasted … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,404],"tags":[],"class_list":["post-474043","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/474043","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=474043"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/474043\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=474043"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=474043"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=474043"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}